1. Clarke S. Protein methylation. Curr Opin
Cell Biol 1993;5:977–983.
2. McBride AE, Silver PA. State of the Arg:
Protein methylation at arginine comes of
age.Cell 2001;106:5–8.
3. Vallance P, Leone A, Calver A, Collier
J, Moncada S. Accumulation of an
endogenous inhibitor of nitric oxide
synthesis in chronic renal failure. Lancet
1992;339:572–575.
4. Vallance P, Leiper J.Cardiovascular Biology
of the Asymmetric Dimethylarginine:
Dimethylarginine Dimethylaminohydrolase
Pathway. Arterioscler Thromb Vas Biol
2004;24:1023-1030.
5. Ogawa T, Kimoto M, Sasaoka K. Purification
and properties of a new enzyme. NG,NGdimethylarginine dimethylaminohydrolase
from rat kidney. J Biol Chem 1989;264:
10205–9.
6. Boger RH, Sydow K, Borlak J, Thum
T, Lenzen H, Schubert B, et al. LDL
cholesterol upregulates synthesis
of asymmetrical dimethylarginine in
human endothelial cells: involvement
of S-adenosylmethionine-dependent
methyltransferases. Circ Res 2000;87:
99–105.
7. Yıldırım AO, Bulau P, Zakrzewicz D,
Kitowska KE, Weissmann N, Grimminger
et al. Increased protein arginine
methylation in chronic hypoxia: Role of
protein arginine methyltransferases. Am J
Respir Cell Mol Biol.2006;35:436-43.
8. Kimoto M, Whitley GS, Tsuji H, Ogawa
T. Detection of NG, NG-dimethylarginine
dimethylaminohydrolase in human tissues
using a monoclonal antibody. J Biochem
1995;117:237–238.
9. John P. Cooke. Does ADMA Cause
Endothelial Dysfunction? Arterioscler
Thromb Vasc Biol 2000;20:2032-2037.
10. Leiper JM, Santa MJ, Chubb A, MacAllister RJ,
Charles IG, Whitley GS, et al. Identification
of two human dimethylarginine
dimethylaminohydrolases with distinct
tissue distributions and homology with
microbial arginine deiminases. Biochem J
1999;343:209–14.
11. Tran Cam TL, Fox MF, Vallance P, Leiper J.
Chromosomal localization, gene structure
and expression pattern of DDAH1:
Comparison with DDAH2 and implications
for evolutionary origins. Genomics
2000;68:101–105.
12. RH Böger. The emerging role of
asymmetric dimethylarginine as a novel
cardiovascular risk factor. Cardiovascular
Research 2003; 59: 824-33.
13. Böger RH, Eyal SR. L-Arginine improves
vascular function by overcoming the
deleterious effects of ADMA, a novel
cardiovascular risk factor. Altern Med Rev
2005; 10(1): 14-23.
14. Radomski MW, Palmer RM, Moncada
S. The anti-aggregating properties of
vascular endothelium: Interactions
between prostacyclin and nitric oxide. Br
J Pharmacol 1987;92:639–46.
15. MacAllister RJ, Parry H, Kimoto M, Ogawa
T, Russell RJ, Hodson H, et al. Regulation of
nitric oxide synthesis by dimethylarginine
dimethylaminohydrolase. Br J Pharmacol
1996; 119: 1533–40.
16. Nijveldt RJ, van Leeuwen PA, Van Guldener
C, Stehouwer CD, Rauwerda JA, Teerlink
T. Net renal extraction of asymmetrical
(ADMA) and symmetrical (SDMA)
dimethylarginine in fasting humans.
Nephrol Dial Transplant 1999–2002: 17.
17. Mark F, McCarty. Medical Hypotheses
2004; 63: 699–708.
18. Vallance P. The asymmetrical
d i m e t h y l a r g i n i n e / d i m e t h y l a r g i n i n e
dimethylaminohydrolase pathway in the
regulation of nitric oxide production. Clin
Sci 2001; 100: 159–60.
19. Stühlinger MC, Tsao PS, Her JH, Kimoto M,
Balint RF, Cooke JP. Homocysteine impairs
the nitric oxide synthase pathway: role of
asymmetric dimethylarginine. Circulation
2001; 104: 2569–75.
20. Lentz SR, Rodionov RN, Dayal S.
Hyperhomocysteinemia, endothelial
dysfunction, and cardiovascular risk: the
potential role of ADMA. Atherosclerosis
Supplements 2003; 4: 61-5.
21. Böger RH, Bode-Böger SM, Heistad DD,
Lentz SR. Elevated plasma concentration
of asymmetric dimethylarginine
(ADMA), an endogenous inhibitor of
nitric oxide synthase, in monkeys with
hyperhomocysteinemia. Circulation 1998;
98: 733.
22. Xiong Y, Fu YF, Fu SH, Zhou HH. Elevated
levels of the serum endogenous inhibitor
of nitric oxide synthase and metabolic
control in rats with streptozotocin induced
diabetes. J Cardiovasc Pharmacol 2003;
42: 191–6.
23. Paiva H, Lehtimaki T, Laakso J,
Ruokonen I, Rantalaiho V, Wirta O, et al.
Plasma concentrations of asymmetricdimethylarginine in type 2 diabetes
associate with glycemic control and
glomerular filtration rate but not with
risk facktors of vasculopathy. Metabolism
2003; 52: 303-7.
24. Yan T, Minxiang L, Sihai F, Yunfeng F.
Effect of diabetic duration on serum
concentrations of endogenous inhibitor of
nitric oxide synthase in patients and rats
with diabetes. Life Sciences 2005; 77:
149–59.
25. Stuhlinger MC, Abbasi F, Chu JV,
Lamendola C, McLaughlin TL, Cooke JP, et
al. Relationship between insulin resistance
and endogenous nitric oxide synthase
inhibitor. JAMA 2002; 287: 1420-6.
26. Lin KY, Ito A, Asagami T, Tsao PS,
Adimoolam S, Kimoto N, et al. Impaired
nitric oxide synthase pathway in
diabetes mellitus:role of asymmetric
dimethylarginine and dimethylarginine
dimethylaminohydrolase. Circulation
2002;106:987-992.
27. Bae SW, Stühlinger MC, Yoo HS, Yu KH,
Park HK, Choi BY, et al. Plasma asymmetric
dimethylarginine concentrations in newly
diagnosed patients with acute myocardial
infarction or unstable angina pectoris
during two weeks of medical treatment.
Am J Cardiol 2005;95:729-733.
28. Zoccali C, Mallamaci F and Tripepi G.
Novel cardiovascular risk factors in end-
stage renal disease. J Am Soc Nephrol
2004; 15: 77-80.
29. Hodis HN, Mack WJ, Labree L, Selzer
RH, Liu CR, Liu CH, et al. The role of
caratoid arterial intima-media thickness
in predicting clinical coronary events.
Ann intern Med 1998; 128: 262-9.
30. Kielstein JT, Böger RH, Bode-Böger SM,
et al. Asymmetric dimethylarginine
plasma concentrations differ in
patients with end-stage renal disease:
Relationship to treatment method
and atherosclerotic disease. J AmSoc
Nephrol 1999; 10: 594-600.
31. Kielstein JT, Zoccali C. Asymmetric
Dymethylarginine: A Cardiovascular risk
factor and a uremic toxin coming of age?
Am J Kidney Dis 2005;46:2:186-202.
32. Speer PD, Powers RW, Frank MP,
Harger G, Markovic N, Roberts JM.
Elevated asymmetric dimethylarginine
concentrations precede clinical
preeclampsia, but not pregnancies with
small-for-gestational-age infants. Am J
Obstet Gynecol 2008;198(1): 112. 1-7.
33. Slaghekke F, Dekker G, Jeffries B.
Endogenous inhibitors of nitric oxide
and preeclampsia: a review. J Matern
Fetal Neonatal Med 2006;19(8):447-52.
34. Kim YJ, Park HS, Lee HY. Reduced Larginine level and decreased placental
eNOS activity in preeclampsia. Placenta
2006; 27(4-5): 438-44.
35. Liuch P, Torondel B,Medina P, Segarra G,
Olmo JA, Serra MA, Rodrigo JM. Plasma
concentrations of nitric oxide and
asymmetric dimethylarginine in human
alcoholic cirrhosis. J Hepatol 2004;
41(1): 55-9.
36. Mookerjee RP, Dalton RN, Davies
NA. Inflammation is an important
determinant of levels of the endogenous
nitric oxide synthase inhibitor
asymmetric dimethylarginine (ADMA) in
acute liver failure. Liver Transpl 2007;
13(3): 400-5.
37. Nijveldt RJ, Teerlink T, Siroen MP Elevation
of asymmetric dimethylarginine (ADMA)
in patients developing hepatic failure
after major hepatectomy. JPEN J Parenter
Enteral Nutr 2004; 28(6): 382-7
38. Anemon A, Backman V, Snygg J, von
Bothmer C, Fandriks L, Petterson A.
Accumulation of an endogeneus inhibitor
of nitric oxide synthase during graded
hemorragic shock. Circ Shock 1994;
44(3): 111-4.
39. Barbera’JA, Peinado VI,Santos S.
Pulmonary hypertesion in chronic
obstructive pulmonary disease. Eur
Respir J 2003; 21: 892-905.
40. Ozgurtas T, Oktenli C, Dede M, Tapan S,
Kenar L, Sanisoglu SY, et al. Metformin
and oral contraceptive treatments
reduced circulating asymmetric
dimethylarginine (ADMA) levels in
patients with polycystic ovary syndrome
(PCOS). Atherosclerosis 2008; 15 [Epub
ahead of print]
41. Yang TL, Chen MF, Xia X, Luo BL, Li
YJ. Effect of fenofibrate on the level
of asymmetric dimethylarginine in
individuals with hypertriglyceridemia.
Eur J Clin Pharmacol 2006; 62: 179-84.
42. Tanaka N, Katayama Y, Katsumata T.
Effects of long-term administration
of HMG-CoA reductase inhibitor,
atorvastatin, on stroke events and local
cerebral blood flow in stroke-prone
spontaneously hypertensive rats. Brain
Res 2007; 12: 125-32.
43. Chen BM, Xia LW, Zhao RQ. Determination
of NG,NG dimethylarginine in human
plasma by high-performance liquid
chromatography. J Chromatogr B 1997;
692: 467–71.
44. Causse E, Siri N, Arnal JF, Bayle C, Malatray
P, Valdiguie P,et al. Determination
of asymmetrical dimethylarginine by
capillary electrophoresis-laser-induced
fluorescence. J Chromatogr B 2000;
741: 77–83.
45. Vishwanathan K, Tackett RL, Stewart JT,
Bartlett MG. Determination of arginine
and methylated arginines in human
plasma by liquid chromatographytandem mass spectrometry. J
Chromatogr B 2000;748:157–166.
46. Tsikas D, Schubert B, Gutzki FM,
Sandmann J, Frölich JC. Quantitative
determination of circulating and urinary
asymmetric dimethylarginine (ADMA) in
humans by gas chromatography-tandem
mass spectrometry as methyl ester tri
(Npentafluoropropionyl) derivative. J
Chromatogr B 2003; 798: 87–99.
47. Schulze F, Wesemann R, Schwedhelm
E, Sydow K, Albsmeier J, Cooke JP,
Böger RH. Determination of asymmetric
dimethylarginine (ADMA) using a novel
ELISA assay. Clin Chem Lab Med 2004;
42: 1377–83.
Thank you for copying data from http://www.arastirmax.com
